Global pharmaceutical launches: ideal start for market access activities should be at least 18 months ahead of launch
Payer relationship activities are especially important to start early, according to Cutting Edge Information.
A new pharmaceutical industry study found that among surveyed companies, market access teams would prefer to start working on products an average of 4.6 months before they currently start supporting new products. According to research from primary intelligence firm Cutting Edge Information, market access groups would ideally start work on launch sequencing and health economics research at least a year and a half before a product launches.
The report, Managing Market Access Launch Activities: Benchmarking Product Commercialization and Cross-Functional Coordination, examines how companies are managing products in the launch window and the pre-launch preparations necessary for a successful product launch. On average, market access teams would ideally prefer to start conducting products support activities 18.7 months before launch, compared with 14.1 months currently.
"Getting market access teams involved earlier allows them to begin laying the groundwork for a successful launch," said Jacob Presson, senior analyst at Cutting Edge Information. "Our research has found that allowing more pre-launch time for market access teams to build effective value cases can make the difference in today's price-sensitive pharmaceutical market." Payer relationship management is currently only entering market access teams' purview around 4.4 months before launch, on average. The study's data show that ideally these activities would begin at least 10 months before launch. Health economics and outcomes research (HEOR) is a particularly important area to begin work well before launch.
"For health economics in particular, a longer lead-in period allows a greater flexibility that adding money in the form of higher budgets simply cannot buy," Presson said. "Clinical studies cannot be rushed and so more time before launch allows teams to collect more robust data to support a new product."
Managing Market Access Launch Activities: Benchmarking Product Commercialization and Cross-Functional Coordination analyses market access teams before and during the crucial launch window, including spending, staffing, and internal coordination.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance